Urologiia (Moscow, Russia : 1999) · 2025
[Efficiency of the biologically active additive Oxaforin in the combined treatment of urolithiasis].
СтатьяРандомизированное исследованиеАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zubkov A Y, Sitdykova M E, Zubkov E A
Аннотация
INTRODUCTION: Treatment of urolithiasis remains an urgent problem related to medical, social and work rehabilitation.
AIM: To evaluate the efficiency of the biologically active additive "Oxaphorin" in the treatment of urolithiasis after extracorporeal shock-wave lithotripsy (ESWL).
MATERIAL AND METHODS: The study included 60 male and female patients from 18 to 75 years old (average age of 45.56+/-12.49 years) with renal stones of up to 10 mm in size, which were disintegrated by the ESWL. All patients were randomized into 3 groups (20 people each). In the first group, patients received standard treatment in the postoperative period (antispasmodics, NSAIDs, uroseptics). In the second group, along with standard therapy, Oxaphorin (1 capsule 2 times a day) was administered, while in the third group Oxaphorin as monotherapy (1 capsule 2 times a day) was given. Treatment and follow-up were carried out in accordance with the study protocol for 30 days. The efficiency of treatment was assessed by the stone-free rate and time to complete evacuation of fragments. Study design included history taking, physical examination, assessment of the tolerability of therapy and adverse events, complete blood count, urinalysis, biochemical panel, ultrasound of the genitourinary system and kidney X-ray.
RESULTS: As the study showed, the rate of stone expulsion was higher in groups of patients receiving Oxaforin. Stone-free rate after 10 days was confirmed using imaging studies and laboratory analyses in 8 (40%) patients of the first group, in 11 (55%) in the second group and in 6 (30%) in the third group. After 1 month of follow-up, stone-free status was confirmed in 16 (80%), 18 (90%) and 15 (75%) patients, respectively. In those taking Oxaforin as part of combined therapy, stone-free rate after ESWL was higher (90% vs. 75% in third group, where Oxaforin was used as monotherapy). The frequency of renal colic and its severity based on a visual analogue scale was significantly lower and less pronounced in patients receiving Oxaforin.
CONCLUSIONS: Our results showed that the biologically active additive "Oxaphorin" has a pronounced effect as medical expulsive therapy without any adverse events and is effective in patients with urinary stone disease after ESWL for kidney stones.
AIM: To evaluate the efficiency of the biologically active additive "Oxaphorin" in the treatment of urolithiasis after extracorporeal shock-wave lithotripsy (ESWL).
MATERIAL AND METHODS: The study included 60 male and female patients from 18 to 75 years old (average age of 45.56+/-12.49 years) with renal stones of up to 10 mm in size, which were disintegrated by the ESWL. All patients were randomized into 3 groups (20 people each). In the first group, patients received standard treatment in the postoperative period (antispasmodics, NSAIDs, uroseptics). In the second group, along with standard therapy, Oxaphorin (1 capsule 2 times a day) was administered, while in the third group Oxaphorin as monotherapy (1 capsule 2 times a day) was given. Treatment and follow-up were carried out in accordance with the study protocol for 30 days. The efficiency of treatment was assessed by the stone-free rate and time to complete evacuation of fragments. Study design included history taking, physical examination, assessment of the tolerability of therapy and adverse events, complete blood count, urinalysis, biochemical panel, ultrasound of the genitourinary system and kidney X-ray.
RESULTS: As the study showed, the rate of stone expulsion was higher in groups of patients receiving Oxaforin. Stone-free rate after 10 days was confirmed using imaging studies and laboratory analyses in 8 (40%) patients of the first group, in 11 (55%) in the second group and in 6 (30%) in the third group. After 1 month of follow-up, stone-free status was confirmed in 16 (80%), 18 (90%) and 15 (75%) patients, respectively. In those taking Oxaforin as part of combined therapy, stone-free rate after ESWL was higher (90% vs. 75% in third group, where Oxaforin was used as monotherapy). The frequency of renal colic and its severity based on a visual analogue scale was significantly lower and less pronounced in patients receiving Oxaforin.
CONCLUSIONS: Our results showed that the biologically active additive "Oxaphorin" has a pronounced effect as medical expulsive therapy without any adverse events and is effective in patients with urinary stone disease after ESWL for kidney stones.